Prevalence and Patterns of Adverse Drug Events Among Adult Patients with Human Immune Virus Infection on Dolutegravir-Based Antiretroviral Drug Regimens in Amhara Comprehensive Specialized Hospitals, Northwest Ethiopia: A Multicenter Retrospective Follow-Up Study

References

• Famil K. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2005.
   Google Scholar
• Dikman AE, Schonfeld E, Srisarajivakul NC, Poles MA. Human immunodeficiency virus-associated diarrhea: still an issue in the era of antiretroviral therapy. Dig Dis Sci. 2015;60(8):2236–2245. doi:10.1007/s10620-015-3615-y
   PubMed Web of Science ®Google Scholar
• Orkin C, Llibre J, Gallien S, Antinori A, Behrens G, Carr A. Nucleoside reverse transcriptase inhibitor‐reducing strategies in HIV treatment: assessing the evidence. HIV Med. 2018;19(1):18–32. doi:10.1111/hiv.12534
   PubMed Web of Science ®Google Scholar
• Cruciani M, Parisi SG. Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: a systematic review and meta-analysis. PLoS One. 2019;14(9):e0222229. doi:10.1371/journal.pone.0222229
   PubMed Web of Science ®Google Scholar
• Snedecor SJ, Radford M, Kratochvil D, Grove R, Punekar YS. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis. BMC Infect Dis. 2019;19(1):1–14. doi:10.1186/s12879-019-3975-6
   PubMedGoogle Scholar
• Drummond MF, Schwartz JS, Jönsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008;24(3):244–258. doi:10.1017/S0266462308080343
   PubMed Web of Science ®Google Scholar
• Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis. 2007;45(8):1093–1101. doi:10.1086/521150
   PubMed Web of Science ®Google Scholar
• Teklay G, Legesse B, Legesse M. Adverse effects and regimen switch among patients on antiretroviral treatment in a resource limited setting in Ethiopia. J Pharmacovigilance. 2013;1(4):115. doi:10.4172/2329-6887.1000115
   Google Scholar
• Tamirat T, Woldemichael K, Tewelde T, Laelago T. Anti-retro viral therapy adverse drug reaction and associated factors among human immuno deficiency virus infected adult patients at Nigist Eleni Mohammed memorial hospital, South Ethiopia. Afr Health Sci. 2020;20(2):560–567. doi:10.4314/ahs.v20i2.3
   PubMed Web of Science ®Google Scholar
• Punekar Y, Parks D, Joshi M, et al. Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real‐world evidence. HIV Med. 2021;22(6):423–433. doi:10.1111/hiv.13050
   PubMed Web of Science ®Google Scholar
• Chen I-W, Sun H-Y, Hung -C-C. Meta-analysis of efficacy and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide among people living with HIV. Infect Dis Ther. 2021;10(3):1331–1346. doi:10.1007/s40121-021-00449-z
   PubMed Web of Science ®Google Scholar
• Sculier D, Wandeler G, Yerly S, et al. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL’HIV trial. PLoS Med. 2020;17(11):e1003421. doi:10.1371/journal.pmed.1003421
   PubMed Web of Science ®Google Scholar
• Del Mar Gutierrez M, Mateo MG, Vidal F, Domingo P. Drug safety profile of integrase strand transfer inhibitors. Expert Opin Drug Saf. 2014;13(4):431–445. doi:10.1517/14740338.2014.897327
   PubMed Web of Science ®Google Scholar
• Mondi A, Cozzi‐Lepri A, Tavelli A, et al. Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort. J Int AIDS Soc. 2019;22(1):e25227. doi:10.1002/jia2.25227
   PubMed Web of Science ®Google Scholar
• Ciccullo A, Baldin G, Borghetti A, Di Giambenedetto S. Dolutegravir plus lamivudine for the treatment of HIV-1 infection. Expert Rev Anti Infect Ther. 2020;18(4):279–292. doi:10.1080/14787210.2020.1729742
   PubMed Web of Science ®Google Scholar
• Goh OQ, Colby DJ, Pinyakorn S, et al. Switch to dolutegravir is well tolerated in Thais with HIV infection. J Int AIDS Soc. 2019;22(7):e25324. doi:10.1002/jia2.25324
   PubMed Web of Science ®Google Scholar
• Peñafiel J, de Lazzari E, Padilla M, et al. Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother. 2017;72(6):1752–1759. doi:10.1093/jac/dkx053
   PubMed Web of Science ®Google Scholar
• Patel R, Evitt L, Mariolis I, et al. HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review. Infect Dis Ther. 2021;10(4):2051–2070. doi:10.1007/s40121-021-00522-7
   PubMed Web of Science ®Google Scholar
• Namulindwa A, Wasswa JH, Muyindike W, Tamukong R, Oloro J. Prevalence and factors associated with adverse drug events among patients on dolutegravir-based regimen at the Immune Suppression Syndrome Clinic of Mbarara Regional Referral Hospital, Uganda: a mixed design study. AIDS Res Ther. 2022;19(1):1–8. doi:10.1186/s12981-022-00442-7
   PubMed Web of Science ®Google Scholar
• Correa A, Monteiro P, Calixto F, Batista J, de Alencar Ximenes RA, Montarroyos UR. Dolutegravir: virologic response and tolerability of initial antiretroviral regimens for adults living with HIV. PLoS One. 2020;15(8):e0238052. doi:10.1371/journal.pone.0238052
   PubMed Web of Science ®Google Scholar
• Bruzzese E, Lo Vecchio A, Smarrazzo A, et al. Dolutegravir-based anti-retroviral therapy is effective and safe in HIV–infected paediatric patients. Ital J Pediatr. 2018;44(1):1–5. doi:10.1186/s13052-018-0469-x
   PubMedGoogle Scholar
• Baldin G, Ciccullo A, Rusconi S, et al. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. Int J Antimicrob Agents. 2019;54(6):728–734. doi:10.1016/j.ijantimicag.2019.09.002
   PubMed Web of Science ®Google Scholar
• Hauser A, Kusejko K, Johnson LF, et al. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: a modeling study. PLoS Med. 2020;17(12):e1003397. doi:10.1371/journal.pmed.1003397
   PubMed Web of Science ®Google Scholar